Medicare Boosts Reimbursement for Oncocyte’s Flagship Technology
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 19 2025
0mins
Should l Buy ?
Source: Globenewswire
New Pricing Announcement: Oncocyte Corp. has increased the reimbursement rate for its GraftAssureCore™ assay to $2,753, enhancing its market potential in transplant rejection testing and aligning with competitive technologies.
Future Prospects: The new pricing sets a benchmark for the upcoming GraftAssureDx product, which is expected to receive FDA review soon, potentially expanding access to high-quality diagnostic kits for transplant centers.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
